Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 147380
Corporate User License Price USD 6000
Corporate User License Price INR 442140
Site License Price USD 4000
Site License Price INR 294760
Request a Quote

Report Title

Chikungunya Fever-Pipeline Review, H1 2017

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Chikungunya Fever-Pipeline Review, H1 2017


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Chikungunya Fever-Pipeline Review, H1 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Chikungunya Fever-Pipeline Review, H1 2017



Executive Summary

Chikungunya Fever-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chikungunya Fever-Pipeline Review, H1 2017, provides an overview of the Chikungunya Fever (Infectious Disease) pipeline landscape.

Chikungunya is a viral disease transmitted to humans by the bite of infected Aedes aegypti mosquitoes. Chikungunya virus (CHIKV) is a member of the genus Alpha virus, in the family Togaviridae. Symptoms of Chikungunya includes debilitating arthralgia (joint pain), swelling of joints, stiffness of joints, myalgia (muscular pain), headache, fatigue (weakness), nausea, vomiting and rash and fever. Treatment includes use of NSAIDs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chikungunya Fever-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chikungunya Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chikungunya Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chikungunya Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 3, 1, 18 and 10 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 5 molecules, respectively.

Chikungunya Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Chikungunya Fever (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Chikungunya Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Chikungunya Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Chikungunya Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Chikungunya Fever (Infectious Disease)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Chikungunya Fever (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Chikungunya Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Chikungunya Fever-Overview

Chikungunya Fever-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Chikungunya Fever-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Chikungunya Fever-Companies Involved in Therapeutics Development

Abivax SA

Arbovax Inc

Arno Therapeutics Inc

Bharat Biotech International Ltd

Ennaid Therapeutics LLC

Etubics Corp

Griffith University

Hawaii Biotech Inc

Indian Immunologicals Ltd

Inovio Pharmaceuticals Inc

Integral Molecular Inc

Integrated BioTherapeutics Inc

Merck & Co Inc

Mymetics Corp

Nanotherapeutics Inc

PaxVax Inc

Profectus BioSciences Inc

Shionogi & Co Ltd

Takeda Pharmaceutical Company Ltd

Themis Bioscience GmbH

Theravectys SA

Valneva SE

Vaxart Inc

Chikungunya Fever-Drug Profiles

(chikungunya + Zika) (bivalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ABX-1089-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ABX-1091-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ABX-311-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AR-12-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BBV-87-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya (viral like particles) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya (viral like particles) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya (virus like particle) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chikungunya vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Chikungunya-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HSRx-431-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMCKV-063-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies for Chikungunya-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies for Equine Encephalitis and Chikungunya-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit CHIKV E2 for Chikungunya-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Target Viral E1 and E2 Proteins for Chikungunya and Ross River Virus Fever-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mRNA-1388-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MV-CHIK-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides for Infectious Diseases-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SCV-305-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit NS2 and NS3 for Chikungunya-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit NS4 for Chikungunya Fever-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Chikungunya-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Chikungunya-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Chikungunya Fever-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Infectious Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides for Chikungunya-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-507-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tatbeclin-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VLA-1553-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chikungunya Fever-Dormant Projects

Chikungunya Fever-Product Development Milestones

Featured News & Press Releases

Jan 09, 2017: Profectus BioSciences Bivalent Vaccine Protects Animals from Infection and Death After Exposure to Chikungunya or Zika Virus

Dec 19, 2016: UTMB researchers develop first chikungunya vaccine from virus that does not affect people

Aug 30, 2016: Hawaii Biotech Awarded Grant To Develop Chikungunya Virus Vaccine

Aug 25, 2016: Leading Chikungunya Vaccine in Clinical Trial Phase 2

Mar 22, 2016: Inovio's DNA-based Monoclonal Antibody and DNA Vaccine Provide 100% Protection Against Lethal Chikungunya Virus Challenge in Preclinical Study

Sep 19, 2015: Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs

Mar 02, 2015: Themis Bioscience's Chikungunya Vaccine Study Results Published in The Lancet Infectious Diseases

Dec 10, 2014: Integral Molecular identifies potent inhibitory antibodies against Chikungunya virus

Nov 20, 2014: Themis Bioscience's Vaccine Against Chikunguya Successful In Phase 1

Aug 14, 2014: Experimental chikungunya vaccine induces robust antibody response

Jun 12, 2014: Threat of Emerging Virus can be Stopped: Interim results of First Clinical Trial of Themis Bioscience's Vaccine Candidate Against Chikungunya Fever Prove Successful

Mar 27, 2013: Themis Bioscience Plans To Initiate Phase I Study Of Chikungunya Fever Vaccine Candidate

Dec 20, 2011: NIAID Enrolls Participants In Chikungunya Vaccine Trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Chikungunya Fever, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

List of Tables

Number of Products under Development for Chikungunya Fever, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Chikungunya Fever-Pipeline by Abivax SA, H1 2017

Chikungunya Fever-Pipeline by Arbovax Inc, H1 2017

Chikungunya Fever-Pipeline by Arno Therapeutics Inc, H1 2017

Chikungunya Fever-Pipeline by Bharat Biotech International Ltd, H1 2017

Chikungunya Fever-Pipeline by Ennaid Therapeutics LLC, H1 2017

Chikungunya Fever-Pipeline by Etubics Corp, H1 2017

Chikungunya Fever-Pipeline by Griffith University, H1 2017

Chikungunya Fever-Pipeline by Hawaii Biotech Inc, H1 2017

Chikungunya Fever-Pipeline by Indian Immunologicals Ltd, H1 2017

Chikungunya Fever-Pipeline by Inovio Pharmaceuticals Inc, H1 2017

Chikungunya Fever-Pipeline by Integral Molecular Inc, H1 2017

Chikungunya Fever-Pipeline by Integrated BioTherapeutics Inc, H1 2017

Chikungunya Fever-Pipeline by Merck & Co Inc, H1 2017

Chikungunya Fever-Pipeline by Mymetics Corp, H1 2017

Chikungunya Fever-Pipeline by Nanotherapeutics Inc, H1 2017

Chikungunya Fever-Pipeline by PaxVax Inc, H1 2017

Chikungunya Fever-Pipeline by Profectus BioSciences Inc, H1 2017

Chikungunya Fever-Pipeline by Shionogi & Co Ltd, H1 2017

Chikungunya Fever-Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Chikungunya Fever-Pipeline by Themis Bioscience GmbH, H1 2017

Chikungunya Fever-Pipeline by Theravectys SA, H1 2017

Chikungunya Fever-Pipeline by Valneva SE, H1 2017

Chikungunya Fever-Pipeline by Vaxart Inc, H1 2017

Chikungunya Fever-Dormant Projects, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Abivax SA, Arbovax Inc, Arno Therapeutics Inc, Bharat Biotech International Ltd, Ennaid Therapeutics LLC, Etubics Corp, Griffith University, Hawaii Biotech Inc, Indian Immunologicals Ltd, Inovio Pharmaceuticals Inc, Integral Molecular Inc, Integrated BioTherapeutics Inc, Merck & Co Inc, Mymetics Corp, Nanotherapeutics Inc, PaxVax Inc, Profectus BioSciences Inc, Shionogi & Co Ltd, Takeda Pharmaceutical Company Ltd, Themis Bioscience GmbH, Theravectys SA, Valneva SE, Vaxart Inc

Chikungunya Fever Therapeutic Products under Development, Key Players in Chikungunya Fever Therapeutics, Chikungunya Fever Pipeline Overview, Chikungunya Fever Pipeline, Chikungunya Fever Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand